Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Tenofovir Compassionate Use Program

September/October 1999

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Gilead has announced a small compassionate access study of tenofovir, a prodrug of PMPA. As with ABT-378, there is limited availability of the drug, so entry criteria are fairly restrictive. Patients must be between 18 and 65, have HIV RNA of at least 10,000 and, in most cases, a CD4 count below 50 cells. Those who have had an active, AIDS-defining opportunistic infection within 90 days and a CD4 count between 50 and 200 cells may also qualify for the program.

For more information, doctors should call (800) 276-0231 weekdays between 8:00 a.m. and 6:00 p.m. (EST).


Back to the GMHC Treatment Issues September/October 1999 contents page.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Gay Men's Health Crisis. It is a part of the publication GMHC Treatment Issues. Visit GMHC's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More News on Tenofovir (Viread)
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement